Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (AG 221, CC 90007) in Subjects With Moderate and Severe Hepatic Impairment.
Conditions
Interventions
Enasidenib
Locations
5
United States
DaVita Clinical Research
Lakewood, Colorado, United States
Clinical Pharmacology of Miami, LLC
Miami, Florida, United States
Orlando Clinical Research Center OCRC
Orlando, Florida, United States
DaVita Clinical Research
Minneapolis, Minnesota, United States
New Orleans Center of Clinical Research
Knoxville, Tennessee, United States
Start Date
September 21, 2017
Primary Completion Date
October 26, 2018
Completion Date
October 26, 2018
Last Updated
July 17, 2020
NCT07324616
NCT04271488
NCT06952634
NCT06841315
NCT06619054
NCT06813781
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions